Home › Books › Validity of some MDS Pharma studies questioned by agency; p…
Validity of some MDS Pharma studies questioned by agency; pending NDAs could be delayed.(Compliance/enforcement): An article from: BioResearch Compliance Report Buy on Amazon

https://www.ebooknetworking.net/books_detail-B000NO3AHI.html

Validity of some MDS Pharma studies questioned by agency; pending NDAs could be delayed.(Compliance/enforcement): An article from: BioResearch Compliance Report

AuthorJoseph Pickett
PublisherThomson Gale
Shop on Amazon — choose your country
🇺🇸 USA 🇨🇦 Canada 🇬🇧 UK 🇩🇪 Germany 🇫🇷 France 🇮🇳 India
Buy New on Amazon 🇫🇷

Book Details

Author(s)Joseph Pickett
PublisherThomson Gale
ISBN / ASINB000NO3AHI
ISBN-13978B000NO3AH3
MarketplaceFrance  🇫🇷

Description

This digital document is an article from BioResearch Compliance Report, published by Thomson Gale on January 1, 2007. The length of the article is 784 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Validity of some MDS Pharma studies questioned by agency; pending NDAs could be delayed.(Compliance/enforcement)
Author: Joseph Pickett
Publication:BioResearch Compliance Report (Newsletter)
Date: January 1, 2007
Publisher: Thomson Gale
Volume: 7 Issue: 1 Page: 1(3)

Distributed by Thomson Gale

More Books by Joseph Pickett

Wyeth hit with 54-item 483 for OOS results, faulty aseptic results, HVAC.(Human drugs): An article from: Validation Times
Wyeth hit with 54-item 483 for OOS results, faulty ase…
View
O'Farrell slapped with 13-item 483 for instrument calibration flaws; owner blasts agency.: An article from: Validation Times
O'Farrell slapped with 13-item 483 for instrument…
View
Mammalian cell technology improving, expert notes; 1-4g/L realized now, 5-10g/L expected soon.(Biotech): An article from: Validation Times
Mammalian cell technology improving, expert notes; 1-4…
View
FDA envisions slight drop in audits for biologics, drugs in FY '06; device inspections to stay even.: An article from: Inspection Monitor
FDA envisions slight drop in audits for biologics, dru…
View
FDA GMP inspections tend to focus on the '6 P's', says Novartis QA representative.(Special Report: Surviving FDA GMP Inspections): An article from: Inspection Monitor
FDA GMP inspections tend to focus on the '6 P…
View
FDA gives pharma companies regulatory relief as they implement PAT.(Process analytical technology): An article from: Validation Times
FDA gives pharma companies regulatory relief as they i…
View
MDS Pharma Services slapped with 3-item 483 concerning contamination following bioequivalence audit.(CROs): An article from: Bioresearch Monitoring Alert
MDS Pharma Services slapped with 3-item 483 concerning…
View
OOS results, media hold-time specifications, flawed validation reports net IDEC 10-item 483.(Biologics): An article from: Validation Times
OOS results, media hold-time specifications, flawed va…
View
23-item 483 issued to Advanced Bionics for quality audits, process validation and risk analysis faults.(Medical devices): An article from: Validation Times
23-item 483 issued to Advanced Bionics for quality aud…
View
Presence of particulate matter in vials top reason for product recalls, Pfizer executive reports at PDA conference.(Recalls): An article from: Validation Times
Presence of particulate matter in vials top reason for…
View
Donate to EbookNetworking
Prev
Next